Inhibition of human immunodeficiency virus type 1 (Hiv-1) replication by the dipyridodiazepinone bi-rg-587

Journal of Infectious Diseases

Volumn 163, Issue 5, 1991, Pages 966-970

  Koup, Richard A ^a   Merluzzi, Vincent J ^a   Hargrave, Karl ^a   Julian, Adams ^a   Grozinger, Karl ^a   Eckner, Robert J ^a   Sullivan, John L ^a  

^a University of Massachusetts Medical School ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; ZIDOVUDINE;

ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TRANSFORMED; GIANT CELLS; HIV-1; HIV-2; HUMAN; NEVIRAPINE; PYRIDINES; RETROVIRIDAE PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VIRUS REPLICATION;

EID: 0025788876     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/163.5.966     Document Type: Article

References (43)

1. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
2. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500-3.
3. Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, Os- hiro LS. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984;225:840-2.
4. Kitchen LW, Barin F, Sullivan JL, et al. Aetiology of AIDS – antibodies to human T-cell leukemia virus (type III) in haemophiliacs. Nature 1984;312:367-9.
5. Baltimore D. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 1970;226:1209-11.
6. Gilboa E, Mitra SW, Goff S, Baltimore D. A detailed model of reversetranscription and tests of crucial aspects. Cell 1974;18:93-100.
7. Dormort D, Spire F, Barre-Sinoussi F, Montagnier L, Chermann JC. Inhibition of RNA-dependent DNA polymerases of AIDS and SAIDS retroviruses by HPA-23 (ammonium-2 l-tungsto-9-antimoniate). Ann Inst Pasteur 1985;136E:75-83.
8. Mitsuya H, Popovic M, Yarchoan R, Matsushita H, Gallo RC. Suramin protection of T-cells in vitro against infectivity and cytopathic effects of HTLV-III. Science 1984;226:172-4.
9. Sandstrom EG, Byington RE, Kaplan JC, Hirsch MS. Inhibition of hu man T-cell lymphotropic virus type HI by phosphonoformate. Lancet 1985;1:1480-2.
10. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-cell lymphotropic virus type III/lymph- adenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096-7100.
11. Vrang L, Oberg B. PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase. Antimicrob Agents Chemother 1986;29:867-72.
12. Toji L, Cohen SS. The enzymatic termination of polydeoxynucleotides by 2'3'-dideoxyadenosinc triphosphate. Proc Natl Acad Sci USA 1969;63:817-7.
13. Yarchoan R, Weinhold KJ, Lyerly HK, et al. Administration of 3'-azido- 3'-deoxythimidine, an inhibitor of HTLV-IH/LAV replication to patients with AIDS or AIDS-related complex. Lancet 1986;1:575-80.
14. Fischl MA, Richman DD, Greico MH, et al. The efficacy of azidothymi- dine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo controlled trial. N Engl J Med 1987;317:185-91.
15. Fischl MA, Richman DD, Hanson N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990;112:727-37.
16. Volberding PA, Lagokos SW, Koch MA, et al. Zidovudine in asymp tomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;332:941-9.
17. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989; 321:1621-5.
18. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731-4.
19. Pluda JM, Yarchoan R, Jaffe ES, et al. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med 1990;113:276-82.
20. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 repli cation by a non-nucleoside reverse transcriptase inhibitor. Science 1990;250:1411-3.
21. Koup RA, Sullivan JL, Levine PH, et al. Antigenic specificity of antibody- dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol 1989;63:584-9.
22. Salahuddin SZ, Markham PD, Wong-Staal F, Franchini G, Kalyanara- man VS, Gallo RC. Restricted expression of human T-cell leukemia- lymphoma virus (HTLV) in transformed umbilical cord blood lymphocytes. Virology 1983;129:51-64.
23. Folks TM, Powell D, Lightfoote M, et al. Biological and biochemical characterization of a cloned Leu3“cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med 1986; 164:280-90.
24. Clavel F, Guetard D, Brun-Vezinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1988;233: 343-6.
25. Gritz L, Destree A, Cormier N, et al. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J Virol 1990;64:5948-57.
26. Sattentau QJ, Dalgleish AG, Weiss RA, Beverley PCL. Epitopes of the CD4 antigen and HIV infection. Science 1986;234:1120-3.
27. + cells. Science 1988;240:646-9.
28. Baba M, Schols D, DeClercq E, et al. Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation. Antimicrob Agents Chemother 1990; 34:134-8.
29. Fisher RA, Bertonis JM, Meier W, et al. HIV infection is blocked in vitro by recombinant soluble CD4. Nature 1988;331:76-8.
30. Hussey RE, Richardson NE, Kowalski M, et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988;331:78-81.
31. Dewar RL, Vasudevachari MB, Natarajan V, Salzman NR Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport. J Virol 1989;63:2452-6.
32. Walker BD, Kowalski M, Goh WC, et al. Inhibition of human im munodeficiency virus syncytium formation and virus replication by castanospermine. Proc Natl Acad Sci USA 1987;84:8120-4.
33. McCormick JB, Getchell JP, Mitchell SW, Hicks DR. Ribavirin sup presses replication of lymphadenopathy associated virus in cultures of human adult T-lymphocytes. Lancet 1984;2:1367-9.
34. Gilbert BE, Knight V. Biochemistry and clinical applications of ribavi. Antimicrob Agents Chemother 1986;30:201-5.
35. Ho DD, Hartshorn KL, Rota TR, et al. Recombinant human interferon alpha A suppresses HTLVIII replication in vitro. Lancet 1985;1:602-4.
36. Pbli G, Orenstein JM, Kinter A, Folks TM, Fauci AS. Interferon-a but not AZT suppresses HIV expression in chronically infected cell lines. Science 1989;244:575-7.
37. Agrawal S, Ikeuchi T, Sun D, et al. Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc Natl Acad Sci USA 1989;86:7790-4.
38. Pauwels R, Andries K, Desmyter J, et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990;343:470-4.
39. Somasundaran M, Robinson HL. Unexpectedly high levels of HIV-1 RNA and protein synthesis in a cytocidal infection. Science 1988;242: 1554-6.
40. Harada S, Koyanagi Y, Yamamoto N. Infection of human T-lymphotropic virus type 1 (HTLV-l)-bearing MT-4 cells with HTLV-HI (AIDS virus): chronological studies of early events. Virology 1985;146:272-81.
41. Robinson HL, Zinkus DM. Accumulation of human immunodeficiency virus type 1 DNA in T cells: result of multiple infection events. J Virol 1990;64:4836-41.
42. Somasundaran M, Robinson HL. A major mechanism of human im munodeficiency virus-induced cell killing does not involve cell fusion. J Virol 1987;61:3114-9.
43. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymi- dine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192-7.